Kuchyne na miru

From the Editor

Aug 20, 2019
Pharmaceutical Executive
By Lisa Henderson
In a sit-down with editors from our group publications, former FDA Commissioner Scott Gottlieb chatted with Pharm Exec on several topics, including the evolution of pricing and reimbursement for novel therapies—and the access fixes needed for future.
Jul 09, 2019
Pharmaceutical Executive
By Lisa Henderson
Highlighting the biggest observations from this year's DIA Annual Meeting—topics likely to continue to dominate industry headlines for the foreseeable future.
Jun 13, 2019
Pharmaceutical Executive
By Lisa Henderson
Our latest report of the top 50 biopharma companies provides a nice springboard to the coverage we have in store for you in the year's second half.
May 08, 2019
Pharmaceutical Executive
By Lisa Henderson
With conference season in high gear, here's the lowdown on our content highlights so far from the event circuit and what to expect on horizon.
Apr 07, 2019
Pharmaceutical Executive
By Lisa Henderson
The lifeblood of our coverage are the many interviews we conduct with industry executives—and the unique stories and insights they provide. Here, I highlight excerpts from a selection of wide-ranging conversations from the past year.
Mar 14, 2019
Pharmaceutical Executive
By Lisa Henderson
That often muddled picture is becoming increasingly clearer in the patient and business context as different ways in which patients, patient communities, advocacy, and pharma engage each other converge.
Feb 08, 2019
Pharmaceutical Executive
By Lisa Henderson
Green-lighting China as our coverage focus in the February issue wasn't without conflict or hesitation, but as our reporting of the nation's biopharma landscape shows, perseverance and growth many times go hand-in-hand.
Jan 01, 2019
Pharmaceutical Executive
By Lisa Henderson
Highlighting a few topics that just missed the cut for our annual Industry Outlook—but are worth keeping a close eye on.
Dec 10, 2018
Pharmaceutical Executive
By Lisa Henderson
In pharma, there may be hope that companies' and the industry's ability to adapt to change may finally be catching up to the pace of new and intelligent uses of technology and clinical data.
Nov 12, 2018
Pharmaceutical Executive
By Lisa Henderson
As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?
native1_300x100
www.techno-centre.niko.ua

капельное орошение

www.chemtest.com.ua/
lorem ipsum